Goldman Sachs: Pfizer and biontech’s vaccine test results may affect the stock market

And its partner, biontech, are expected to release the results of the new coronavirus trial in September, which may determine the fate of the global economy and affect the share prices of other companies developing new coronavirus drugs; Goldman Sachs expects Pfizer and biontech to have a 50% chance of success. Analysts such as Terence Flynn wrote that if this turns out to be the case, it could be detrimental to the share prices of other pharmaceutical companies developing vaccines, especially Merck and Johnson & Johnson. < / P > < p > as investors will expect sales of radcivir to decline, Gilead science may also weaken; the same is true for pharmaceutical companies that develop antibody therapy, such as regenerant and Eli Lilly.